Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 730357 + itraconazole is a **combination of BI 730357, an oral small molecule inhibitor of the retinoic acid-related orphan receptor gamma t (RORγt), and itraconazole, a triazole antifungal agent**. BI 730357 is investigated primarily for moderate-to-severe plaque psoriasis and psoriatic arthritis. Its mechanism involves selective inhibition of RORγt, a key transcription factor promoting pathogenic Th17 cell differentiation and interleukin-17 production, which are implicated in autoimmune diseases like psoriasis[1][3][4][6]. Itraconazole acts by inhibiting the fungal enzyme lanosterol 14α-demethylase, blocking ergosterol synthesis and thus compromising the fungal cell membrane[2]. This combination has been studied in phase 1 pharmacokinetic and drug-drug interaction trials to assess potential effects of itraconazole on BI 730357 metabolism[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BI 730357 + itraconazole.